

CONTINUING EDUCATION ACTIVITY OVERVIEW

Title: Identification, Diagnosis and Management of Chronic Kidney Disease and Secondary Hyperparathyroidism

Format: Webcast

Purpose Statement: This activity is designed to provide health care professionals with a comprehensive update on chronic kidney disease (CKD) prevalence, risk factors and staging. The use of glomerular filtration rate and microalbuminuria as disease indicators in CKD is examined. New areas of research focusing on Chronic Kidney Disease Bone-Mineral Disorder (CKD-MBD), secondary hyperparathyroidism and hyperphosphatemia in CKD are discussed along with their clinical relevance.

Objectives	Content (Topics)	Timeframe	Faculty	Teaching Methods
List learners' objectives in behavioral terms.	Provide an outline of the content for each objective. It must be more than a restatement of the objective.	State timeframe for each objective.	List the Faculty for each objective.	Describe the teaching methods, strategies, materials & resources used for each objective
Describe the prevalence, risk factors and staging of chronic kidney disease and the use of GFR and microalbuminuria as disease indicators	<ul style="list-style-type: none"> • CKD Prevalence • Introduction to the field of bone and mineral metabolism in CKD • Definition and Classification of Chronic Kidney Disease • Strengths and limitations of CKD testing • Testing for Kidney Damage <ul style="list-style-type: none"> ○ Proteinuria ○ Microalbuminuria • Measurement And Estimation of Kidney Function 	15 mins	Grahame Elder, MB BS, PhD, FRACP David Wheeler, MD, FRCP	Audio webcast Slides, figures, charts

<p>Discuss the diagnosis of CKD-MBD and Secondary Hyperparathyroidism in early CKD</p>	<ul style="list-style-type: none"> • Definition of CKD-MBD—A systemic disorder of mineral and bone metabolism due to CKD • Diagnosis of bone and mineral disorders in CKD • Monitoring frequency and target ranges of biomarkers • Introduction to Secondary Hyperparathyroidism • Discussion of the factors that contribute to Secondary Hyperparathyroidism • Hyperphosphatemia prevalence • Biochemical markers of bone and mineral metabolism 	<p>15 mins</p>	<p>Grahame Elder, MB BS, PhD, FRACP</p> <p>Cathi Martin, RD, CSR, LDN</p>	<p>Audio webcast Slides, figures, charts</p>
<p>Identify the range of treatment options for secondary hyperparathyroidism and hyperphosphatemia including side effects of therapy</p>	<ul style="list-style-type: none"> • Clinical Manifestations of Renal Bone Disease in CKD • Managing calcium and phosphorus metabolism and controlling PTH function in patients with earlier stages of CKD • The treatment modalities for bone disease in CKD: • Treatment choices for secondary hyperparathyroidism (SHPT) in early CKD <ul style="list-style-type: none"> ○ Hyperphosphatemia treatment ○ Restriction of dietary phosphate intake commensurate with stage of CKD ○ Dietary phosphate binders ○ Oral calcium supplements ○ Vitamin D or its derivatives ○ Calcimimetics 	<p>20 mins</p>	<p>David Wheeler, MD, FRCP</p> <p>Cathi Martin, RD, CSR, LDN</p>	<p>Audio webcast Slides, figures, charts</p>
	<p>Post-test and evaluation</p>	<p>10 mins</p>	<p>n/a</p>	<p>n/a</p>